
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated a consistent upward trajectory in processing EsoGuard tests, with an increase from 2,756 tests in Q2 to 2,841 tests in Q3, highlighting a positive trend in utilization of its diagnostic product offerings. Additionally, the company's valuation appears favorable, with an NPV analysis indicating significant upside potential when balancing the associated risks of its business model. The ongoing commercialization of PAVmed's products, coupled with expectations for substantial growth in the coming years, further supports optimism for the company's financial future.
Bears say
PAVmed Inc has reported a pro forma net loss of $0.8 million, resulting in an earnings per share (EPS) of $(0.05), which is better than previous estimates but reflects ongoing financial challenges. Additionally, the company experienced a decline in EsoGuard test processes, with only 2,756 tests conducted in Q2 compared to higher volumes in preceding quarters, indicating reduced demand for its diagnostic product. Furthermore, PAVmed's Lucid business remains in the early stages of commercialization, and the firm faces multiple risks, including liquidity concerns, regulatory hurdles, and competition, which contribute to a negative outlook on its financial health and future growth potential.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares